Clinical trial
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating…
NCT00005988 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00005988 |
|---|---|
| Title | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy |
| Official title | A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloma |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, in vitro-treated bone marrow transplantation, radiation therapy |
| Enrollment | 5 |
| Start date | Feb 1, 2000 |
| Primary completion | Jun 16, 2001 |
| Completion | Mar 8, 2002 |
| First posted | May 3, 2004 |
| Last update posted | Apr 4, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: